Tokyo Tape
Sign in
← Trans Genic Group

Half-year report · Q2

2342.TEDINET S100UI5X
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥6.3bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥13.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥111m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥157m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥108m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥195m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥182m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥185m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥10.6bnat 2024-09-30Cons.Assets
Total assets¥9.8bnat 2024-03-31Cons.Assets
Total assets¥10.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥5.8bnat 2024-09-30Cons.Net assets
Net assets / equity¥6.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥2.5bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥2.2bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥421m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥392m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥175m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥281m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥379m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥343m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-10.972024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.242023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio53.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio60.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥114m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥806m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥803m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥189m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥45,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥192m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥3m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Operating incomePrior1YTDDuration88523000JPY
Operating incomeCurrentYTDDuration-110769000JPY
Interest income noiPrior1YTDDuration51000JPY
Interest income noiCurrentYTDDuration252000JPY
Foreign exchange gains noiPrior1YTDDuration34216000JPY
Foreign exchange gains noiCurrentYTDDuration－JPY
Insurance income noiPrior1YTDDuration3061000JPY
Insurance income noiCurrentYTDDuration2397000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration－JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration4271000JPY
Other noiPrior1YTDDuration4490000JPY
Other noiCurrentYTDDuration4693000JPY
Non operating incomePrior1YTDDuration41820000JPY
Non operating incomeCurrentYTDDuration11615000JPY
Interest expenses noePrior1YTDDuration24297000JPY
Interest expenses noeCurrentYTDDuration18448000JPY
Foreign exchange losses noePrior1YTDDuration－JPY
Foreign exchange losses noeCurrentYTDDuration2664000JPY
Acquisition expenses noePrior1YTDDuration－JPY
Acquisition expenses noeCurrentYTDDuration27705000JPY
Loss on sales of notes payable noePrior1YTDDuration3502000JPY
Loss on sales of notes payable noeCurrentYTDDuration1804000JPY
Other noePrior1YTDDuration7752000JPY
Other noeCurrentYTDDuration6754000JPY
Non operating expensesPrior1YTDDuration35552000JPY
Non operating expensesCurrentYTDDuration57377000JPY
Ordinary incomePrior1YTDDuration94791000JPY
Ordinary incomeCurrentYTDDuration-156532000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration74000JPY
Extraordinary incomePrior1YTDDuration－JPY
Extraordinary incomeCurrentYTDDuration74000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration708000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration5658000JPY
Retirement benefit expenses elPrior1YTDDuration－JPY
Retirement benefit expenses elCurrentYTDDuration32884000JPY
Extraordinary lossPrior1YTDDuration708000JPY
Extraordinary lossCurrentYTDDuration38543000JPY
Income before income taxesPrior1YTDDuration94083000JPY
Income before income taxesCurrentYTDDuration-195001000JPY
Income taxes currentPrior1YTDDuration32720000JPY
Income taxes currentCurrentYTDDuration24216000JPY
Income taxes deferredPrior1YTDDuration19171000JPY
Income taxes deferredCurrentYTDDuration-34164000JPY
Income taxesPrior1YTDDuration51891000JPY
Income taxesCurrentYTDDuration-9948000JPY
Profit lossPrior1YTDDuration42192000JPY
Profit lossCurrentYTDDuration-185053000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration-6272000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration-2793000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass